concussion Swiss Firm Marker Diagnostics Developing Saliva-Based Concussion Assay Premium The firm said it believes that the results of a recent study are representative of the broader utility of the test and its potential for broad application to diagnose concussions. Quadrant Biosciences Wins $2.3M NIH Grant to Develop Saliva Test for Concussion The company and its collaborators previously published a study linking saliva concentrations of multiple microRNAs with concussion duration and symptoms in children. Quadrant Biosciences Licenses SUNY, Penn State Epigenetic Biomarkers for Neuro Diseases The company hopes to develop saliva-based RNA assays for concussion, Parkinson's disease and autism using biomarkers discovered by its two academic partners. BU, Seqster Partner on Traumatic Brain Injury Study Newly launched aggregator Seqster will help Boston University researchers collect data from EHRs, wearables, and gene tests to identify concussion biomarkers. Oxford BioDynamics, Holos to Develop Biomarkers for Sports-Related Concussions The partners will perform blood-based tests on Oxford's Episwitch platform to monitor epigenetic changes of athletes with concussions. Mar 3, 2017 Abbott in Collaborations to Develop Biomarker Test for Traumatic Brain Injury Mar 30, 2016 ADx NeuroSciences, Quanterix Ink Deal to Develop Blood-Based Concussion Test Jun 11, 2014 TGen Gets Funding for Football Concussion Research May 14, 2013 TGen, Riddell Team Up on Molecular-based Study of Concussions Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.